Skip to main content
Top
Published in: PharmacoEconomics 10/2023

Open Access 21-06-2023 | Parkinson's Disease | Systematic Review

Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review

Authors: Judith Dams, Johann-Jacob Zapp, Hans-Helmut König

Published in: PharmacoEconomics | Issue 10/2023

Login to get access

Abstract

Objective

This article systematically reviewed the methodological quality of modelling approaches for economic evaluations of the treatment of motor symptoms in Parkinson’s disease in studies published after 2010.

Methods

A systematic literature search was undertaken using PubMed, EconLit, the Cochrane Database of Systematic Reviews, National Health Service Economic Evaluation Database and Health Technology Assessment databases of the UK National Health Service Centre for Review and Dissemination (March 2010 to July 2022). Quality was assessed using a checklist from the German Scientific Working Group.

Results

A total of 20 studies were evaluated, with the majority based on Markov models (n = 18). Studies assessed the cost effectiveness of medical (n = 12) or surgical (n = 8) treatment, and included costs from a payer or healthcare provider’s perspective (n = 17). Furthermore, all studies included quality-adjusted life-years as an effect measure. In the quality assessment of the literature, a mean score of 42.1 points (out of 56 points) on the checklist of the German Scientific Working Group was achieved. Seventeen studies concluded the intervention under study was (likely) cost effective. No intervention was classified as cost ineffective.

Conclusions

The quality of economic evaluation models in Parkinson’s disease has improved in terms of calculating cost and transition parameters, as well as carrying out probabilistic sensitivity analyses, compared with the published literature of previous systematic reviews up to 2010. However, there is still potential for further development in terms of the integration of non-motor complications and treatment changes, the transparent presentation of parameter estimates, as well as conducting sensitivity analyses and validations to support the interpretation of results.
Appendix
Available only for authorised users
Literature
1.
go back to reference Afentou N, Jarl J, Gerdtham UG, Saha S. Economic evaluation of interventions in Parkinson’s disease: a systematic literature review. Mov Disord Clin Pract. 2019;6(4):282–90.PubMedPubMedCentralCrossRef Afentou N, Jarl J, Gerdtham UG, Saha S. Economic evaluation of interventions in Parkinson’s disease: a systematic literature review. Mov Disord Clin Pract. 2019;6(4):282–90.PubMedPubMedCentralCrossRef
2.
go back to reference Becerra JE, Zorro O, Ruiz-Gaviria R, Castañeda-Cardona C, Otálora-Esteban M, Henao S, et al. Economic analysis of deep brain stimulation in Parkinson disease: systematic review of the literature. World Neurosurg. 2016;93:44–9.PubMedCrossRef Becerra JE, Zorro O, Ruiz-Gaviria R, Castañeda-Cardona C, Otálora-Esteban M, Henao S, et al. Economic analysis of deep brain stimulation in Parkinson disease: systematic review of the literature. World Neurosurg. 2016;93:44–9.PubMedCrossRef
3.
go back to reference Dang TTH, Rowell D, Connelly LB. Cost-effectiveness of deep brain stimulation with movement disorders: a systematic review. Mov Disord Clin Pract. 2019;6(5):348–58.PubMedPubMedCentralCrossRef Dang TTH, Rowell D, Connelly LB. Cost-effectiveness of deep brain stimulation with movement disorders: a systematic review. Mov Disord Clin Pract. 2019;6(5):348–58.PubMedPubMedCentralCrossRef
4.
go back to reference García-Álvarez D, Sempere-Rubio N, Faubel R. Economic evaluation in neurological physiotherapy: a systematic review. Brain Sci. 2021;11(2). García-Álvarez D, Sempere-Rubio N, Faubel R. Economic evaluation in neurological physiotherapy: a systematic review. Brain Sci. 2021;11(2).
5.
go back to reference Mahajan UV, Ravikumar VK, Kumar KK, Ku S, Ojukwu DI, Kilbane C, et al. Bilateral deep brain stimulation is the procedure to beat for advanced Parkinson disease: a meta-analytic, cost-effective threshold analysis for focused ultrasound. Neurosurgery. 2021;88(3):487–96.PubMedCrossRef Mahajan UV, Ravikumar VK, Kumar KK, Ku S, Ojukwu DI, Kilbane C, et al. Bilateral deep brain stimulation is the procedure to beat for advanced Parkinson disease: a meta-analytic, cost-effective threshold analysis for focused ultrasound. Neurosurgery. 2021;88(3):487–96.PubMedCrossRef
6.
go back to reference Marsili L, Bologna M, Miyasaki JM, Colosimo C. Parkinson’s disease advanced therapies: a systematic review: more unanswered questions than guidance. Parkinsonism Relat Disord. 2021;83:132–9.PubMedCrossRef Marsili L, Bologna M, Miyasaki JM, Colosimo C. Parkinson’s disease advanced therapies: a systematic review: more unanswered questions than guidance. Parkinsonism Relat Disord. 2021;83:132–9.PubMedCrossRef
7.
go back to reference Scope A, Bhadhuri A, Pennington B. Systematic review of cost-utility analyses that have included carer and family member health-related quality of life. Value Health. 2022;25(9):1644–53.PubMedCrossRef Scope A, Bhadhuri A, Pennington B. Systematic review of cost-utility analyses that have included carer and family member health-related quality of life. Value Health. 2022;25(9):1644–53.PubMedCrossRef
8.
go back to reference Smilowska K, van Wamelen DJ, Pietrzykowski T, Calvano A, Rodriguez-Blazquez C, Martinez-Martin P, et al. Cost-effectiveness of device-aided therapies in Parkinson’s disease: a structured review. J Parkinsons Dis. 2021;11(2):475–89.PubMedPubMedCentralCrossRef Smilowska K, van Wamelen DJ, Pietrzykowski T, Calvano A, Rodriguez-Blazquez C, Martinez-Martin P, et al. Cost-effectiveness of device-aided therapies in Parkinson’s disease: a structured review. J Parkinsons Dis. 2021;11(2):475–89.PubMedPubMedCentralCrossRef
9.
go back to reference Wang AS, Gunzler SA. Systematic review of the pharmacoeconomics of Parkinson disease medications. Expert Opin Pharmacother. 2019;20(13):1659–70.PubMedCrossRef Wang AS, Gunzler SA. Systematic review of the pharmacoeconomics of Parkinson disease medications. Expert Opin Pharmacother. 2019;20(13):1659–70.PubMedCrossRef
10.
go back to reference Winser SJ, Paul LF, Magnus LKL, Yan S, Shenug TP, Sing YM, et al. Economic evaluation of exercise-based fall prevention programs for people with Parkinson’s disease: a systematic review. J Altern Complement Med. 2019;25(12):1225–37.PubMedCrossRef Winser SJ, Paul LF, Magnus LKL, Yan S, Shenug TP, Sing YM, et al. Economic evaluation of exercise-based fall prevention programs for people with Parkinson’s disease: a systematic review. J Altern Complement Med. 2019;25(12):1225–37.PubMedCrossRef
12.
go back to reference Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79.PubMedCrossRef Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79.PubMedCrossRef
13.
go back to reference Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, et al. The long-term direct and indirect economic burden among Parkinson’s disease caregivers in the United States. Mov Disord. 2019;34(2):236–45.PubMedCrossRef Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, et al. The long-term direct and indirect economic burden among Parkinson’s disease caregivers in the United States. Mov Disord. 2019;34(2):236–45.PubMedCrossRef
14.
go back to reference Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9: 776847.PubMedPubMedCentralCrossRef Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9: 776847.PubMedPubMedCentralCrossRef
15.
16.
go back to reference Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9.PubMedCrossRef Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9.PubMedCrossRef
17.
go back to reference Dams J, Bornschein B, Reese JP, Conrads-Frank A, Oertel WH, Siebert U, et al. Modelling the cost effectiveness of treatments for Parkinson’s disease: a methodological review. Pharmacoeconomics. 2011;29(12):1025–49.PubMedCrossRef Dams J, Bornschein B, Reese JP, Conrads-Frank A, Oertel WH, Siebert U, et al. Modelling the cost effectiveness of treatments for Parkinson’s disease: a methodological review. Pharmacoeconomics. 2011;29(12):1025–49.PubMedCrossRef
18.
go back to reference Shearer J, Green C, Counsell CE, Zajicek JP. The use of decision-analytic models in Parkinson’s disease: a systematic review and critical appraisal. Appl Health Econ Health Policy. 2011;9(4):243–58.PubMedCrossRef Shearer J, Green C, Counsell CE, Zajicek JP. The use of decision-analytic models in Parkinson’s disease: a systematic review and critical appraisal. Appl Health Econ Health Policy. 2011;9(4):243–58.PubMedCrossRef
19.
go back to reference Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic assessment of decision models in Parkinson’s disease. Value Health. 2004;7(5):610–26.PubMedCrossRef Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic assessment of decision models in Parkinson’s disease. Value Health. 2004;7(5):610–26.PubMedCrossRef
20.
go back to reference Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
21.
go back to reference Siebert U, Behrend C, Mühlberger N, Wasem J, Greiner W, Graf von der Schulenburg J, et al. Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland. In: Leidl R, Graf von der Schulenburg J, Wasem J, editors. Baden-Baden: Nomos Verlagsgesellschaft; 1999: p. 156–70. Siebert U, Behrend C, Mühlberger N, Wasem J, Greiner W, Graf von der Schulenburg J, et al. Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland. In: Leidl R, Graf von der Schulenburg J, Wasem J, editors. Baden-Baden: Nomos Verlagsgesellschaft; 1999: p. 156–70.
22.
go back to reference Arnold R, Layton A, Rustay N, Chen S. Cost-effectiveness of extended-release carbidopa-levodopa for advanced Parkinson’s disease. Am J Pharm Benefits. 2017;9(1):23–9. Arnold R, Layton A, Rustay N, Chen S. Cost-effectiveness of extended-release carbidopa-levodopa for advanced Parkinson’s disease. Am J Pharm Benefits. 2017;9(1):23–9.
23.
go back to reference Canadian Agency for Drugs and Technologies in Health. CADTH Common Drug Review: pharmacoeconomic review report: apomorphine (Movapo): indication: the acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson’s disease. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2018. Canadian Agency for Drugs and Technologies in Health. CADTH Common Drug Review: pharmacoeconomic review report: apomorphine (Movapo): indication: the acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson’s disease. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2018.
24.
go back to reference Chaudhuri KR, Pickard AS, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Bao Y, et al. The cost effectiveness of levodopa-carbidopa intestinal gel in the treatment of advanced Parkinson’s disease in England. Pharmacoeconomics. 2022;40(5):559–74.PubMedPubMedCentralCrossRef Chaudhuri KR, Pickard AS, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Bao Y, et al. The cost effectiveness of levodopa-carbidopa intestinal gel in the treatment of advanced Parkinson’s disease in England. Pharmacoeconomics. 2022;40(5):559–74.PubMedPubMedCentralCrossRef
25.
go back to reference Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, et al. Cost-effectiveness of neurostimulation in Parkinson’s disease with early motor complications. Mov Disord. 2016;31(8):1183–91.PubMedCrossRef Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, et al. Cost-effectiveness of neurostimulation in Parkinson’s disease with early motor complications. Mov Disord. 2016;31(8):1183–91.PubMedCrossRef
26.
go back to reference Dams J, Siebert U, Bornschein B, Volkmann J, Deuschl G, Oertel WH, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson’s disease. Mov Disord. 2013;28(6):763–71.PubMedCrossRef Dams J, Siebert U, Bornschein B, Volkmann J, Deuschl G, Oertel WH, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson’s disease. Mov Disord. 2013;28(6):763–71.PubMedCrossRef
27.
go back to reference Eggington S, Valldeoriola F, Chaudhuri KR, Ashkan K, Annoni E, Deuschl G. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s disease. J Neurol. 2014;261(1):106–16.PubMedCrossRef Eggington S, Valldeoriola F, Chaudhuri KR, Ashkan K, Annoni E, Deuschl G. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s disease. J Neurol. 2014;261(1):106–16.PubMedCrossRef
28.
go back to reference Fann JC, Chang KC, Yen AM, Chen SL, Chiu SY, Chen HH, et al. Cost-effectiveness analysis of deep brain stimulation for Parkinson disease in Taiwan. World Neurosurg. 2020;138:e459–68.PubMedCrossRef Fann JC, Chang KC, Yen AM, Chen SL, Chiu SY, Chen HH, et al. Cost-effectiveness analysis of deep brain stimulation for Parkinson disease in Taiwan. World Neurosurg. 2020;138:e459–68.PubMedCrossRef
29.
go back to reference Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early Parkinson disease therapies. Am J Pharm Benefits. 2012;4:99–107. Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early Parkinson disease therapies. Am J Pharm Benefits. 2012;4:99–107.
30.
go back to reference Fundament T, Eldridge PR, Green AL, Whone AL, Taylor RS, Williams AC, et al. Deep brain stimulation for Parkinson’s disease with early motor complications: a UK cost-effectiveness analysis. PLoS ONE. 2016;11(7): e0159340.PubMedPubMedCentralCrossRef Fundament T, Eldridge PR, Green AL, Whone AL, Taylor RS, Williams AC, et al. Deep brain stimulation for Parkinson’s disease with early motor complications: a UK cost-effectiveness analysis. PLoS ONE. 2016;11(7): e0159340.PubMedPubMedCentralCrossRef
31.
go back to reference Groenendaal H, Tarrants ML, Armand C. Treatment of advanced Parkinson’s disease in the United States: a cost-utility model. Clin Drug Investig. 2010;30(11):789–98.PubMedCrossRef Groenendaal H, Tarrants ML, Armand C. Treatment of advanced Parkinson’s disease in the United States: a cost-utility model. Clin Drug Investig. 2010;30(11):789–98.PubMedCrossRef
32.
go back to reference Hansen RN, Suh K, Serbin M, Yonan C, Sullivan SD. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. J Med Econ. 2021;24(1):563–9. Hansen RN, Suh K, Serbin M, Yonan C, Sullivan SD. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. J Med Econ. 2021;24(1):563–9.
33.
go back to reference Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson’s disease in patients in Scotland and Wales. J Med Econ. 2019;22(3):215–25.PubMedCrossRef Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson’s disease in patients in Scotland and Wales. J Med Econ. 2019;22(3):215–25.PubMedCrossRef
34.
go back to reference Kawamoto Y, Mouri M, Taira T, Iseki H, Masamune K. Cost-effectiveness analysis of deep brain stimulation in patients with Parkinson’s disease in Japan. World Neurosurg. 2016;89:628-35.e1.PubMedCrossRef Kawamoto Y, Mouri M, Taira T, Iseki H, Masamune K. Cost-effectiveness analysis of deep brain stimulation in patients with Parkinson’s disease in Japan. World Neurosurg. 2016;89:628-35.e1.PubMedCrossRef
35.
go back to reference Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. J Med Econ. 2011;14(5):584–93.PubMedCrossRef Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. J Med Econ. 2011;14(5):584–93.PubMedCrossRef
36.
go back to reference Lowin J, Sail K, Baj R, Jalundhwala YJ, Marshall TS, Konwea H, et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. J Med Econ. 2017;20(11):1207–15.PubMedCrossRef Lowin J, Sail K, Baj R, Jalundhwala YJ, Marshall TS, Konwea H, et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. J Med Econ. 2017;20(11):1207–15.PubMedCrossRef
37.
go back to reference Meng Y, Pople CB, Kalia SK, Kalia LV, Davidson B, Bigioni L, et al. Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson’s disease. J Neurosurg. 2020;7:1–6. Meng Y, Pople CB, Kalia SK, Kalia LV, Davidson B, Bigioni L, et al. Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson’s disease. J Neurosurg. 2020;7:1–6.
38.
go back to reference Pietzsch JB, Garner AM, Marks WJ Jr. Cost-effectiveness of deep brain stimulation for advanced Parkinson’s disease in the United States. Neuromodulation. 2016;19(7):689–97.PubMedCrossRef Pietzsch JB, Garner AM, Marks WJ Jr. Cost-effectiveness of deep brain stimulation for advanced Parkinson’s disease in the United States. Neuromodulation. 2016;19(7):689–97.PubMedCrossRef
39.
go back to reference Thach A, Kirson N, Zichlin ML, Dieye I, Pappert E, Williams GR. Cost-effectiveness of apomorphine sublingual film as an “on-demand” treatment for “OFF” episodes in patients with Parkinson’s disease. J Health Econ Outcomes Res. 2021;8(2):82–92.PubMedPubMedCentralCrossRef Thach A, Kirson N, Zichlin ML, Dieye I, Pappert E, Williams GR. Cost-effectiveness of apomorphine sublingual film as an “on-demand” treatment for “OFF” episodes in patients with Parkinson’s disease. J Health Econ Outcomes Res. 2021;8(2):82–92.PubMedPubMedCentralCrossRef
40.
go back to reference van Boven JF, Novak A, Driessen MT, Boersma C, Boomsma MM, Postma MJ. Economic evaluation of ropinirole prolonged release for treatment of Parkinson’s disease in the Netherlands. Drugs Aging. 2014;31(3):193–201.PubMedCrossRef van Boven JF, Novak A, Driessen MT, Boersma C, Boomsma MM, Postma MJ. Economic evaluation of ropinirole prolonged release for treatment of Parkinson’s disease in the Netherlands. Drugs Aging. 2014;31(3):193–201.PubMedCrossRef
41.
go back to reference Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany. J Med Econ. 2015;18(2):155–65.PubMedCrossRef Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany. J Med Econ. 2015;18(2):155–65.PubMedCrossRef
42.
go back to reference Clarke CE. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord. 1995;10(3):250–6.PubMedCrossRef Clarke CE. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord. 1995;10(3):250–6.PubMedCrossRef
43.
go back to reference Davey P, Rajan N, Lees M, Aristides M. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson’s disease: a decision-analytic model. Value Health. 2001;4(4):308–15.PubMedCrossRef Davey P, Rajan N, Lees M, Aristides M. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson’s disease: a decision-analytic model. Value Health. 2001;4(4):308–15.PubMedCrossRef
44.
go back to reference Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, et al. Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21(9):1384–95.PubMedCrossRef Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, et al. Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21(9):1384–95.PubMedCrossRef
45.
go back to reference Herlofson K, Lie SA, Arsland D, Larsen JP. Mortality and Parkinson disease: a community based study. Neurology. 2004;62(6):937–42.PubMedCrossRef Herlofson K, Lie SA, Arsland D, Larsen JP. Mortality and Parkinson disease: a community based study. Neurology. 2004;62(6):937–42.PubMedCrossRef
46.
go back to reference Hobson P, Meara J, Ishihara-Paul L. The estimated life expectancy in a community cohort of Parkinson’s disease patients with and without dementia, compared with the UK population. J Neurol Neurosurg Psychiatry. 2010;81(10):1093–8.PubMedCrossRef Hobson P, Meara J, Ishihara-Paul L. The estimated life expectancy in a community cohort of Parkinson’s disease patients with and without dementia, compared with the UK population. J Neurol Neurosurg Psychiatry. 2010;81(10):1093–8.PubMedCrossRef
47.
go back to reference Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, et al. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(4):321–6.PubMedCrossRef Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, et al. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(4):321–6.PubMedCrossRef
48.
go back to reference Liou HH, Wu CY, Chiu YH, Yen AM, Chen RC, Chen TF, et al. Mortality of Parkinson's disease by Hoehn–Yahr stage from community-based and clinic series [Keelung Community-based Integrated Screening (KCIS) no. 17)]. J Eval Clin Pract. 2009;15(4):587–91. Liou HH, Wu CY, Chiu YH, Yen AM, Chen RC, Chen TF, et al. Mortality of Parkinson's disease by Hoehn–Yahr stage from community-based and clinic series [Keelung Community-based Integrated Screening (KCIS) no. 17)]. J Eval Clin Pract. 2009;15(4):587–91.
49.
go back to reference Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology. 2005;64(1):87–93.PubMedCrossRef Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology. 2005;64(1):87–93.PubMedCrossRef
50.
go back to reference Posada IJ, Benito-León J, Louis ED, Trincado R, Villarejo A, Medrano MJ, et al. Mortality from Parkinson’s disease: a population-based prospective study (NEDICES). Mov Disord. 2011;26(14):2522–9.PubMedCrossRef Posada IJ, Benito-León J, Louis ED, Trincado R, Villarejo A, Medrano MJ, et al. Mortality from Parkinson’s disease: a population-based prospective study (NEDICES). Mov Disord. 2011;26(14):2522–9.PubMedCrossRef
51.
go back to reference Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson’s disease. Acta Neurol Scand. 1995;92(1):55–8.PubMedCrossRef Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson’s disease. Acta Neurol Scand. 1995;92(1):55–8.PubMedCrossRef
52.
go back to reference Xu J, Gong DD, Man CF, Fan Y. Parkinson’s disease and risk of mortality: meta-analysis and systematic review. Acta Neurol Scand. 2014;129(2):71–9.PubMedCrossRef Xu J, Gong DD, Man CF, Fan Y. Parkinson’s disease and risk of mortality: meta-analysis and systematic review. Acta Neurol Scand. 2014;129(2):71–9.PubMedCrossRef
53.
go back to reference Nuijten MJ, van Iperen P, Palmer C, van Hilten BJ, Snyder E. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health. 2001;4(4):316–28. Nuijten MJ, van Iperen P, Palmer C, van Hilten BJ, Snyder E. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health. 2001;4(4):316–28.
54.
go back to reference Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for “off-time” outcomes in the treatment of Parkinson’s disease. Qual Life Res. 2000;9(7):819–27.PubMedCrossRef Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for “off-time” outcomes in the treatment of Parkinson’s disease. Qual Life Res. 2000;9(7):819–27.PubMedCrossRef
55.
go back to reference Palmer CS, Nuijten MJ, Schmier JK, Subedi P, Snyder EH. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics. 2002;20(9):617–28.PubMedCrossRef Palmer CS, Nuijten MJ, Schmier JK, Subedi P, Snyder EH. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics. 2002;20(9):617–28.PubMedCrossRef
56.
go back to reference Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson’s disease. Neurology. 2002;59(1):103–8.PubMedCrossRef Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson’s disease. Neurology. 2002;59(1):103–8.PubMedCrossRef
57.
go back to reference Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, et al. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics. 2005;23(8):817–36.PubMedCrossRef Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, et al. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics. 2005;23(8):817–36.PubMedCrossRef
58.
go back to reference Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19(2):135–44.PubMedCrossRef Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19(2):135–44.PubMedCrossRef
59.
go back to reference Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD. An economic model of Parkinson’s disease: implications for slowing progression in the United States. Mov Disord. 2013;28(3):319–26.PubMedCrossRef Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD. An economic model of Parkinson’s disease: implications for slowing progression in the United States. Mov Disord. 2013;28(3):319–26.PubMedCrossRef
60.
go back to reference Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov Disord. 2009;24(4):564–73.PubMedCrossRef Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov Disord. 2009;24(4):564–73.PubMedCrossRef
61.
go back to reference Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–91.PubMedCrossRef Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–91.PubMedCrossRef
62.
go back to reference Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001;56(11 Suppl 5):S1-88.PubMedCrossRef Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001;56(11 Suppl 5):S1-88.PubMedCrossRef
63.
go back to reference Hudry J, Rinne JO, Keränen T, Eckert L, Cochran JM. Cost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in Finland. Ann Pharmacother. 2006;40(4):651–7.PubMedCrossRef Hudry J, Rinne JO, Keränen T, Eckert L, Cochran JM. Cost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in Finland. Ann Pharmacother. 2006;40(4):651–7.PubMedCrossRef
64.
go back to reference Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947–54. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947–54.
65.
go back to reference Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med. 1982;73(6):883–8. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med. 1982;73(6):883–8.
66.
go back to reference Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson’s disease: progression and mortality in the L-DOPA era. Adv Neurol. 1996;69:3–11.PubMed Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson’s disease: progression and mortality in the L-DOPA era. Adv Neurol. 1996;69:3–11.PubMed
67.
go back to reference Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26(7):1259–65.PubMedCrossRef Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26(7):1259–65.PubMedCrossRef
68.
go back to reference Marttila RJ, Rinne UK. Disability and progression in Parkinson’s disease. Acta Neurol Scand. 1977;56(2):159–69.PubMedCrossRef Marttila RJ, Rinne UK. Disability and progression in Parkinson’s disease. Acta Neurol Scand. 1977;56(2):159–69.PubMedCrossRef
69.
go back to reference Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 2003;349(20):1925–34.PubMedCrossRef Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 2003;349(20):1925–34.PubMedCrossRef
70.
go back to reference Schüpbach WM, Chastan N, Welter ML, Houeto JL, Mesnage V, Bonnet AM, et al. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1640–4.PubMedPubMedCentralCrossRef Schüpbach WM, Chastan N, Welter ML, Houeto JL, Mesnage V, Bonnet AM, et al. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1640–4.PubMedPubMedCentralCrossRef
71.
go back to reference Valldeoriola F, Pilleri M, Tolosa E, Molinuevo JL, Rumià J, Ferrer E. Bilateral subthalamic stimulation monotherapy in advanced Parkinson’s disease: long-term follow-up of patients. Mov Disord. 2002;17(1):125–32.PubMedCrossRef Valldeoriola F, Pilleri M, Tolosa E, Molinuevo JL, Rumià J, Ferrer E. Bilateral subthalamic stimulation monotherapy in advanced Parkinson’s disease: long-term follow-up of patients. Mov Disord. 2002;17(1):125–32.PubMedCrossRef
72.
go back to reference Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73.PubMedPubMedCentralCrossRef Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73.PubMedPubMedCentralCrossRef
73.
go back to reference Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, Lau PN, et al. Progression of Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord. 2010;25(6):710–6.PubMedCrossRef Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, Lau PN, et al. Progression of Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord. 2010;25(6):710–6.PubMedCrossRef
74.
go back to reference Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368(7):610–22.PubMedCrossRef Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368(7):610–22.PubMedCrossRef
75.
go back to reference Bond AE, Shah BB, Huss DS, Dallapiazza RF, Warren A, Harrison MB, et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol. 2017;74(12):1412–8.PubMedPubMedCentralCrossRef Bond AE, Shah BB, Huss DS, Dallapiazza RF, Warren A, Harrison MB, et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol. 2017;74(12):1412–8.PubMedPubMedCentralCrossRef
Metadata
Title
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
Authors
Judith Dams
Johann-Jacob Zapp
Hans-Helmut König
Publication date
21-06-2023
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 10/2023
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-023-01289-0

Other articles of this Issue 10/2023

PharmacoEconomics 10/2023 Go to the issue